CEVI Stock Overview
Develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for CEVI from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
CellaVision AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 192.00 |
| 52 Week High | SEK 302.00 |
| 52 Week Low | SEK 147.80 |
| Beta | 1.23 |
| 1 Month Change | 28.00% |
| 3 Month Change | -2.04% |
| 1 Year Change | -27.41% |
| 3 Year Change | -41.82% |
| 5 Year Change | -35.83% |
| Change since IPO | 1,130.77% |
Recent News & Updates
There's Reason For Concern Over CellaVision AB (publ)'s (STO:CEVI) Massive 29% Price Jump
May 04
Is There Now An Opportunity In CellaVision AB (publ) (STO:CEVI)?
Apr 30Recent updates
There's Reason For Concern Over CellaVision AB (publ)'s (STO:CEVI) Massive 29% Price Jump
May 04Is There Now An Opportunity In CellaVision AB (publ) (STO:CEVI)?
Apr 30CellaVision (STO:CEVI) Is Increasing Its Dividend To SEK2.50
Apr 03
Next-generation Digital Cell Morphology Analyzer Will Drive Future Product Development
Strategic alignment with Sysmex and innovation are driving growth, enhancing revenue and future earnings potential.CellaVision (STO:CEVI) Is Increasing Its Dividend To SEK2.50
Feb 11Analyst Estimates: Here's What Brokers Think Of CellaVision AB (publ) (STO:CEVI) After Its Annual Report
Feb 10CellaVision AB (publ)'s (STO:CEVI) Share Price Could Signal Some Risk
Feb 08Is Now The Time To Put CellaVision (STO:CEVI) On Your Watchlist?
Jan 21Does CellaVision (STO:CEVI) Have A Healthy Balance Sheet?
Nov 20CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Oct 27CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Jul 24Is CellaVision (STO:CEVI) A Risky Investment?
Jun 07Does CellaVision (STO:CEVI) Deserve A Spot On Your Watchlist?
May 22CellaVision (STO:CEVI) Is Due To Pay A Dividend Of SEK2.25
Apr 13CellaVision AB (publ)'s (STO:CEVI) Intrinsic Value Is Potentially 46% Above Its Share Price
Apr 09CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
Mar 28CellaVision's (STO:CEVI) Dividend Will Be SEK2.25
Mar 14CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
Feb 29After Leaping 28% CellaVision AB (publ) (STO:CEVI) Shares Are Not Flying Under The Radar
Feb 16CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
Feb 12Earnings Beat: CellaVision AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 10CellaVision's (STO:CEVI) Returns On Capital Not Reflecting Well On The Business
Dec 13Is Now An Opportune Moment To Examine CellaVision AB (publ) (STO:CEVI)?
Sep 14Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)
Aug 22CellaVision (STO:CEVI) Is Reinvesting At Lower Rates Of Return
Jun 17CellaVision's (STO:CEVI) Upcoming Dividend Will Be Larger Than Last Year's
May 07Estimating The Fair Value Of CellaVision AB (publ) (STO:CEVI)
Apr 19CellaVision (STO:CEVI) Is Increasing Its Dividend To SEK2.25
Apr 05CellaVision (STO:CEVI) Is Paying Out A Larger Dividend Than Last Year
Mar 04CellaVision AB (publ) (STO:CEVI) Analysts Are More Bearish Than They Used To Be
Feb 11Is CellaVision (STO:CEVI) A Risky Investment?
Jan 13Is CellaVision AB (publ) (STO:CEVI) Potentially Undervalued?
Dec 13Shareholder Returns
| CEVI | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -1.0% | 3.2% | 0.5% |
| 1Y | -27.4% | -15.7% | -3.6% |
Return vs Industry: CEVI underperformed the Swedish Medical Equipment industry which returned -15.7% over the past year.
Return vs Market: CEVI underperformed the Swedish Market which returned -3.6% over the past year.
Price Volatility
| CEVI volatility | |
|---|---|
| CEVI Average Weekly Movement | 8.3% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in SE Market | 13.7% |
| 10% least volatile stocks in SE Market | 4.2% |
Stable Share Price: CEVI has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: CEVI's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 228 | Simon Ostergaard | www.cellavision.com |
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials.
CellaVision AB (publ) Fundamentals Summary
| CEVI fundamental statistics | |
|---|---|
| Market cap | SEK 4.60b |
| Earnings (TTM) | SEK 152.12m |
| Revenue (TTM) | SEK 747.94m |
Is CEVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CEVI income statement (TTM) | |
|---|---|
| Revenue | SEK 747.94m |
| Cost of Revenue | SEK 235.72m |
| Gross Profit | SEK 512.22m |
| Other Expenses | SEK 360.10m |
| Earnings | SEK 152.12m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 18, 2025
| Earnings per share (EPS) | 6.38 |
| Gross Margin | 68.48% |
| Net Profit Margin | 20.34% |
| Debt/Equity Ratio | 2.7% |
How did CEVI perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 19:51 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CellaVision AB (publ) is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sten Gustafsson | ABG Sundal Collier |
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Carl-Oscar Bredengen | Berenberg |